Sterling Capital Management LLC Sells 3,265 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Sterling Capital Management LLC lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 57.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,422 shares of the biopharmaceutical company’s stock after selling 3,265 shares during the quarter. Sterling Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $598,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ALNY. Toth Financial Advisory Corp acquired a new position in Alnylam Pharmaceuticals in the third quarter worth about $25,000. Keating Financial Advisory Services Inc. acquired a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $42,000. Burkett Financial Services LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $37,000. CoreCap Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 744.4% during the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 134 shares in the last quarter. Finally, Ascentis Independent Advisors bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at approximately $64,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Barclays dropped their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Stifel Nicolaus dropped their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Oppenheimer cut their price target on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Wells Fargo & Company reduced their price target on shares of Alnylam Pharmaceuticals from $256.00 to $253.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 14th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $364.95.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $232.40 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $482.73. The firm’s 50 day moving average is $239.15 and its 200-day moving average is $288.34. The firm has a market capitalization of $31.10 billion, a price-to-earnings ratio of 43.20 and a beta of 0.28. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter last year, the business posted ($0.51) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 66.9% compared to the same quarter last year. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.